U.S. Insomnia Market worth 4.24 Billion USD by 2021

1
MarketsandMarkets Presents

• U.S. Insomnia Market
•  - Global Forecasts to 2021

2

• The U.S. insomnia market is projected to reach
  USD 4.24 Billion by 2021 from USD 3.38 Billion in
  2016, at a CAGR of 4.6 during the forecast
  period. In this report, the U.S. insomnia market
  is segmented on the basis of type of treatment.
• Based on type of treatment, the U.S. insomnia
  market is categorized into pharmacological
  treatments and non-pharmacological treatments.
  The pharmacological treatments segment is further
  categorized into prescription sleep aids and
  over-the-counter sleep aids. The over-the-counter
  sleep aids segment is estimated to grow at the
  highest CAGR during the forecast period due to
  easier availability and low price as compared to
  prescription sleep aids. Moreover, according to
  consumer reports, a patient can save up to USD 47
  a week using OTC sleep aids.

3
http//www.marketsandmarkets.com/Market-Repor
ts/us-insomnia-market-55727597.html Based on
non-pharmacological treatment, the market is
categorized into cognitive behavioural therapy
for insomnia (CBTI), hypnotherapy, and other
alternative therapies. CBTI is highly recommended
therapy for insomnia patients due as its can be
used with multiple approaches that enables
physicians to understand and cure patients
comprehensibly. The other alternative therapies
include exercise/yoga, acupuncture, biofeedback,
bright light therapy, music therapy, and aroma
therapy.
4

• The prescription sleep aids market is segmented
  into non-benzodiazepines, benzodiazepines, orexin
  antagonists, melatonin receptor agonist, and
  other prescription sleep aids. The
  non-benzodiazepines segment is further
  categorized into zolpidem, eszopiclone, and
  zaleplon. In 2016, zolpidem is expected to
  account for the largest share of the
  non-benzodaizepines market for insomnia. However,
  higher adoption of generic products that are
  available are cheaper price is negatively
  affecting the growth of the market. Other
  prescription sleep aids include sleep aids such
  as antipsychotics, chloral derivatives, and
  tricyclic antidepressants.
• Key players operating in the U.S. insomnia market
  are Eisai, Co. Ltd. (Japan), Merck Co., Inc.
  (U.S.), Meda Consumer Healthcare Inc. (U.S.),
  Pfizer, Inc. (U.S.), Sanofi (France), Takeda
  Pharmaceutical Company Ltd. (Japan), Pernix
  Therapeutics (U.S.), and Purdue Pharma L.P.
  (U.S.).

5
Contact Us

• Mr. RohanMarkets and Markets UNIT no 802, Tower
  no. 7, SEZMagarpatta city, HadapsarPune,
  Maharashtra 411013, India1-888-600-6441Email
  sales_at_marketsandmarkets.com
• MarketsandMarkets Blog
• http//www.linkedin.com/company/marketsandmarkets
• http//twitter.com/marketsmarkets

6
About MarketsandMarkets
MarketsandMarkets is a global market research and
consulting company based in the U.S. We publish
strategically analyzed market research reports
and serve as a business intelligence partner to
Fortune 500 companies across the
world. MarketsandMarkets also provides
multi-client reports, company profiles,
databases, and custom research services. They
cover thirteen industry verticals, including
advanced materials, automotives and
transportation, banking and financial services,
biotechnology, chemicals, consumer goods, energy
and power, food and beverages, industrial
automation, medical devices, pharmaceuticals,
semiconductor and electronics, and
telecommunications and IT. We at
MarketsandMarkets are inspired to help our
clients grow by providing apt business insight
with our huge market intelligence repository.